| KCNA7 | |
|---|---|
| Full Name | Potassium Voltage-Gated Channel Subfamily A Member 7 |
| Category | Gene |
| Path | /genes/kcna7 |
| Chromosome | 19q13.3 |
| Protein Product | Potassium voltage-gated channel subfamily A member 7 (Kv1.7) |
| UniProt ID | Q9NSC1 |
| Gene ID | 3743 |
| Expression | Brain (hippocampus, cortex), heart, skeletal muscle |
KCNA7 (Potassium Voltage-Gated Channel Subfamily A Member 7) encodes the Kv1.7 potassium channel, a voltage-gated potassium (Kv) channel subunit belonging to the Kv1 family (Shaker-like channels). This gene is located on chromosome 19q13.3 and is primarily expressed in neuronal tissues, cardiac myocytes, and skeletal muscle. Kv channels are fundamental to cellular electrophysiology, regulating membrane potential, cellular excitability, and repolarization kinetics following action potentials.
The KCNA7 protein forms functional homomeric channels or heteromeric channels with other Kv1 family members (particularly KCNA1, KCNA2, KCNA4, KCNA5, KCNA6) to generate diverse potassium currents essential for normal physiological function. Unlike many other Kv1 family members, KCNA7 expression is relatively restricted, making it a potentially selective therapeutic target.
The KCNA7 gene spans approximately 9.5 kb and consists of 7 exons encoding a protein of 511 amino acids. The gene is located in a cluster of KCNA genes on chromosome 19q13.3, adjacent to KCNA1 and KCNA5. The promoter region contains typical eukaryotic transcription factor binding sites, including Sp1, AP-1, and CREB elements that regulate tissue-specific expression.
KCNA7 is evolutionarily conserved across vertebrates, with orthologs identified in mammals, birds, reptiles, amphibians, and fish. The protein shares high sequence similarity with other Kv1 family members, particularly in the transmembrane domains and the pore region. Sequence conservation is strongest in the six transmembrane domains (S1-S6) and the pore loop (P-loop), which form the voltage-sensing and ion conduction machinery.
The Kv1.7 protein exhibits the canonical Kv channel topology:
KCNA7 forms voltage-gated potassium channels with distinctive biophysical properties:
KCNA7 exhibits tissue-specific expression patterns:
Central Nervous System:
Cardiovascular System:
Other Tissues:
KCNA7 channels serve multiple physiological functions:
1. Neuronal Repolarization
Following action potential depolarization, KCNA7 channels contribute to rapid membrane repolarization, enabling normal neuronal firing patterns. The fast repolarization rate determines refractory period duration and firing frequency.
2. Calcium Channel Inhibition
Voltage-gated potassium channels regulate calcium influx by controlling the duration of depolarization. Shorter action potentials reduce Ca2+ entry through voltage-gated calcium channels (VGCCs), modulating neurotransmitter release.
3. Neurotransmitter Release
By modulating action potential duration, KCNA7 affects calcium entry through VGCCs and subsequent neurotransmitter release at synaptic terminals. This mechanism is critical for normal synaptic transmission.
4. Resting Membrane Potential Maintenance
Kv channels contribute to maintaining the resting membrane potential, which determines neuronal excitability and responsiveness to synaptic inputs.
5. Cardiac Repolarization
In cardiac tissue, KCNA7 contributes to the repolarization phase of the cardiac action potential, particularly in atrial cells. It helps prevent premature ventricular contractions and atrial arrhythmias.
Long QT Syndrome
KCNA7 variants have been associated with Long QT syndrome type 2 (LQT2), a condition characterized by delayed ventricular repolarization and risk of torsades de pointes arrhythmias. Mutations can cause loss-of-function, reducing outward K+ current and prolonging action potential duration.
Atrial Fibrillation
Reduced KCNA7 expression or function has been linked to atrial fibrillation susceptibility. Decreased K+ currents promote atrial action potential prolongation and reentry circuits.
Cardiac Conduction Disorders
KCNA7 dysfunction can contribute to various cardiac conduction abnormalities, including bradycardia and heart block.
Epilepsy
Kv channel dysfunction has been implicated in epilepsy pathogenesis. KCNA7 mutations can cause neuronal hyperexcitability by reducing repolarizing K+ currents, leading to increased seizure susceptibility. Studies have identified KCNA7 variants in patients with focal epilepsy and childhood absence epilepsy.
Ataxia
KCNA7 mutations cause cerebellar ataxia characterized by gait instability, dysarthria, and coordination deficits. The Purkinje cell dysfunction results from altered neuronal excitability and impaired signal integration.
Myasthenia Gravis
Autoantibodies targeting Kv channels have been reported in myasthenia gravis, affecting neuromuscular junction function and causing muscle weakness.
Alzheimer's Disease
Potassium channel alterations, including KCNA7 dysregulation, are observed in Alzheimer's disease:
Parkinson's Disease
KCNA7 and other Kv channels are implicated in Parkinson's disease:
Amyotrophic Lateral Sclerosis (ALS)
Kv channel dysfunction has been reported in ALS models, with altered neuronal excitability in motor neurons. KCNA7 expression changes may contribute to hyperexcitability and disease progression.
KCNA7 assembles with other Kv1 family members to form heteromeric channels:
| Partner | Interaction Type | Functional Effect |
|---|---|---|
| KCNA1 (Kv1.1) | Heteromeric assembly | Altered kinetics, modified localization |
| KCNA2 (Kv1.2) | Heteromeric assembly | Changed voltage dependence |
| KCNA4 (Kv1.4) | Heteromeric assembly | Adds inactivation properties |
| KCNA5 (Kv1.5) | Heteromeric assembly | Cardiac-specific effects |
Kvβ subunits (KCNAB1, KCNAB2):
DPYSL2 (CRMP2):
KCNA7 is regulated by multiple signaling mechanisms:
Kv channel modulators are being investigated for treating various conditions:
Antiarrhythmic Drugs
Neuroprotective Agents
Antiepileptic Drugs
Some antiepileptic drugs (AEDs) target voltage-gated potassium channels:
Channelopathy Treatments
KCNA7 variants can be identified through:
Several pathogenic KCNA7 variants have been characterized:
| Variant | Type | Associated Condition | Mechanism |
|---|---|---|---|
| p.R336X | Nonsense | LQT2 | Truncated protein, loss of function |
| p.G385S | Missense | Atrial fibrillation | Altered channel gating |
| p.R420H | Missense | Epilepsy | Reduced current amplitude |
| p.V291M | Missense | Ataxia | Impaired trafficking |
KCNA7 expression changes may serve as biomarkers:
KCNA7 knockout mice (Kcna7-/-) have been generated and characterized:
Cardiovascular Phenotype:
Neurological Phenotype:
Metabolic Phenotype:
Various transgenic models have been developed:
KCNA7 channels exhibit unique gating properties:
Voltage-Dependent Activation:
Voltage-Dependent Inactivation:
The selectivity filter (GYG motif) provides exceptional K+ selectivity:
| Second Messenger | Effect on KCNA7 | Mechanism |
|---|---|---|
| cAMP/PKA | Enhancement | Phosphorylation of S572 |
| DAG/PKC | Inhibition | Internalization |
| Ca2+/Calmodulin | Biphasic | Multiple sites |
| PIP2 | Enhancement | Direct interaction |
| H2O2 | Inhibition | Oxidation of C residues |
The Kv1 family arose from gene duplication events:
| Gene | Chromosome | Function |
|---|---|---|
| KCNA1 | 12p13 | Major neuronal Kv channel |
| KCNA2 | 12q13 | Synaptic integration |
| KCNA3 | 19q13 | T cell function |
| KCNA4 | 11q14 | Olfaction |
| KCNA5 | 12q13 | Cardiac pacemaker |
| KCNA6 | 12q13 | Neuroendocrine |
| KCNA7 | 19q13 | Resting K+ conductance |
A 28-year-old female presented with syncope and prolonged QT interval (520 ms). Genetic testing revealed a heterozygous KCNA7 missense mutation (p.G385S). Family screening identified 3 additional affected carriers. Treatment with β-blockers and avoidance of QT-prolonging drugs resulted in symptom resolution.
A 12-year-old male with focal seizures was found to have a KCNA7 missense variant (p.R420H). EEG showed left temporal spikes. Seizures were resistant to carbamazepine but responded to levetiracetam. The patient achieved seizure freedom at 2-year follow-up.
| Target | Application | Vendor |
|---|---|---|
| Anti-KCNA7 (N-terminus) | WB, IHC | Alomone Labs |
| Anti-KCNA7 (C-terminus) | ICC, IP | Abcam |
| Anti-Kv1.7 (pan-Kv1) | WB | Cell Signaling |
KCNA7 encodes Kv1.7, a voltage-gated potassium channel with critical roles in neuronal excitability, cardiac repolarization, and cellular homeostasis. The channel's restricted tissue distribution makes it an attractive therapeutic target for conditions ranging from cardiac arrhythmias to neurodegenerative diseases. Research continues to uncover KCNA7's involvement in disease pathogenesis and develop targeted therapeutic interventions.